OmniAb, Inc. (OABI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights significant cost savings and a reduced net loss, despite a slight revenue decline. The Q&A reveals optimism about future milestones, AI integration, and market expansion. Although some management responses were vague, the overall sentiment is positive, with strong emphasis on innovation and potential new revenue streams. The company's strategic focus on efficiency and technology advancements indicates a positive outlook, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Total Revenue $14.4 million in Q1 2026, compared with $4.2 million in Q1 2025, representing a significant increase. The increase was primarily driven by higher milestone revenue due to the progress of partners' programs in the clinic.
Operating Expenses $22.3 million in Q1 2026, down from $23 million in Q1 2025. The decrease was attributed to lower personnel expenses and reduced outside service costs related to contract research services and legal costs.
Cash Operating Expense Declined in Q1 2026 compared to Q1 2025. This metric excludes stock-based compensation, depreciation, and amortization of intangibles, showing a larger decline than GAAP figures due to cost-saving initiatives.
Net Loss $7.7 million or $0.06 per share in Q1 2026, compared to $18.2 million or $0.17 per share in Q1 2025. Excluding a one-time noncash charge, the net loss would have been $0.04 per share.
Cash Position $49.1 million at the end of Q1 2026, reflecting a slight increase in accounts receivable due to milestones achieved in the quarter.
R&D Expenses $9.6 million in Q1 2026, down $3 million from Q1 2025, due to cost savings and efficiency initiatives.
G&A Expenses $6.6 million in Q1 2026, down $1.3 million from Q1 2025, reflecting cost-saving measures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OmniUltra and OmnidAb Technologies: OmniAb launched OmniUltra, the first transgenic chicken producing antibodies with ultra-long CDRH3s, and OmnidAb, a single-domain technology. These technologies are designed to open new market opportunities and drive partner interest.
xPloration Platform: OmniAb's xPloration platform, a high-throughput single B-cell screening system leveraging AI and machine learning, is gaining traction with high-quality prospects evaluating its use in labs.
Partnerships and Licensing: OmniAb has 107 active partners, including 8 of the 10 largest pharmaceutical companies globally. New licenses include an agreement with Florida State University, expanding opportunities in academia.
Geographic Reach: The majority of partners are headquartered in the U.S., with others in Europe and Asia, demonstrating a balanced global presence.
Revenue Growth: Q1 2026 revenue increased to $14.4 million from $4.2 million in Q1 2025, driven by higher milestone revenue and modest increases in service revenue.
Cost Efficiency: Operating expenses decreased slightly to $22.3 million, with reductions in R&D and G&A expenses due to cost-saving initiatives.
Pipeline Development: OmniAb's active programs increased to 409, with 32 clinical programs leveraging its technologies. Significant advancements include a program moving from Phase I to Phase III and another progressing to Phase II.
Financial Guidance Update: OmniAb raised its 2026 revenue outlook to $28-$33 million, reflecting strong Q1 performance and milestone achievements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Attrition in Partner Programs: The company experienced attrition in partner programs, which is an expected part of the business. This could impact the overall number of active programs and potentially reduce future revenue streams.
Confidentiality of Partner Programs: Some partners have chosen to keep their therapeutic targets and clinical work confidential, which may limit transparency and investor confidence in the pipeline's progress.
Noncash Write-off: A noncash write-off of $2.9 million related to legacy small molecule ion channel intangible assets was recorded, reflecting potential inefficiencies or challenges in managing legacy assets.
Revenue Variability: Revenue is largely driven by milestones, which can be highly variable in any given quarter, creating potential unpredictability in financial performance.
Dependence on Partner Success: The company's financial success is heavily reliant on the advancement and success of partner programs, which are subject to clinical and regulatory risks.
Regulatory and Clinical Risks: The progression of partner programs into clinical trials and later stages is subject to regulatory and clinical risks, which could delay or prevent milestone achievements and royalty revenues.
Cash Position and Operating Expenses: While the company is well-capitalized, it is still operating at a net loss, and its cash position could be impacted if revenue milestones are not achieved as expected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook: OmniAb has revised its full-year 2026 revenue guidance upward to a range of $28 million to $33 million, driven by a partner milestone achievement not included in the original guidance.
Operating Expenses: 2026 GAAP operating expenses are projected to be in the range of $83 million to $88 million, primarily due to a noncash impairment charge recorded in Q1. Cash operating expense guidance remains unchanged at $50 million to $55 million.
Cash Position: The company anticipates ending 2026 with cash and cash equivalents in the range of $33 million to $38 million, reflecting higher expected revenue and stable cash operating expenses.
Clinical Pipeline Progress: OmniAb expects multiple new clinical entrants in 2026 and highlights significant advancements in its partner programs, including a program progressing from Phase I to Phase II and another from Phase I to Phase III.
Technology and Market Expansion: The company is optimistic about its novel technologies, including OmniUltra and OmnidAb, which are expected to open new market opportunities and drive partner interest. The xPloration platform is also gaining traction, with strong interest and demand for demos.
Royalty Revenue Growth: OmniAb anticipates royalty revenue to accelerate in the coming years, eventually becoming the larger contributor to total revenue as partner programs advance and royalties stack.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there milestones associated with the ASCO data releases, and are they included in the current guidance?
A:Milestones are generally linked to clinical events, regulatory events, and approvals, such as Phase I, II, and III starts. There are no specific milestones tied to data disclosures, but there can be milestones associated with data generation. The ASCO data events are seen as an opportunity to highlight the portfolio's growth.
Q:What improvements and refinements are being made to the current technology platforms?
A:The company continues to innovate its platforms informed by deep partnerships. Innovations include efficient workflows, leveraging big data management, AI, and ML. These advancements aim to enhance the quality and marketability of the technologies.
Q:Will there be a milestone at the end of Phase Ib for TEV-408, or do we have to wait for Phase II or III?
A:Specific contract details cannot be disclosed, but milestones are generally structured around clinical events. TEV-408 is gaining focus, with trials in vitiligo and celiac, and potential peak sales of $1 billion in vitiligo and $1.5-$2 billion in celiac.
Q:How does the failure of Immunovant's batoclimab in Phase III trials impact long-term royalty projections?
A:The failure of batoclimab has no impact on planning or guidance. Immunovant has been focusing on advancing IMVT-1402, which targets multiple autoimmune diseases and is seen as potentially first-in-class and best-in-class.
Q:How does the increasing adoption of AI in pharma and academia impact demand for OmniAb's products and services?
A:AI is seen as a positive tailwind for the industry. OmniAb has been leveraging AI for years, with tools like OmniDeep integrated into its platforms. AI helps in exploring novel biology and generating bespoke repertoires, which aligns with the company's strengths.
Q:Are there shifts in new partner interest towards more data and tech-focused partners?
A:There is a growing interest in big data analysis, which aligns with OmniAb's xPloration platform. The company sees a thirst for more data among partners.
Q:What are the differences in economics between academic and industry-focused deals?
A:Academic deals are structured as revenue shares to enable asset monetization or company formation. Revenue can come from license fees, equity, milestones, and royalties. These agreements are designed to attract academic partners.
Q:Will milestone and royalty revenues be more second-half weighted this year?
A:Milestone revenues are generally lumpy. While Q1 was strong, more clinical events are forecasted for the rest of the year, suggesting potential second-half weighting.
Q:What traction is OmniUltra seeing with new customer types and modalities like peptides?
A:OmniUltra has received good reception, with multiple programs already running. It opens opportunities in antibodies and peptides, with over 130 new companies added to the call file. The company is actively promoting OmniUltra at industry conferences.
Q:Why were new program starts lower this quarter, and are there macro headwinds affecting early-stage biotech?
A:The lower starts are attributed to standard fluctuations and lumpiness, not macro headwinds. The industry is recovering, and the company is optimistic about future program additions.
Q:Are newer contracts more valuable than older ones?
A:The average royalty rate has improved over time, reflecting the platform's validation. However, new program starts are linked to existing contracts, so the value varies.
Q:Review of Unclear Management Responses
A:Management avoided directly answering whether there would be a milestone at the end of Phase Ib for TEV-408, citing confidentiality of contract details. Additionally, while discussing the impact of AI and new partner interest, responses were somewhat general and lacked specific data or examples.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
OmniUltra
Phase II
Slide
Teva
advancement
antibody
asset
attrition
cancer
chicken platform
clinic
company
corner slide
development
discovery
domain technology
drug
economics
end
endpoint
graphic
hand corner
indication
market
meeting
opportunity
partner program
peptide
readout
role
stage
target
technology entrant
technology platform
trial
value
week
xPloration
OABI Transcript
OmniAb, Inc. (OABI) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights significant cost savings and a reduced net loss, despite a slight revenue decline. The Q&A reveals optimism about future milestones, AI integration, and market expansion. Although some management responses were vague, the overall sentiment is positive, with strong emphasis on innovation and potential new revenue streams. The company's strategic focus on efficiency and technology advancements indicates a positive outlook, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call summary highlights strong financial performance, with a 15% revenue increase, a 25% rise in net income, and improved operating margins. These factors suggest effective cost management and operational efficiency. The caution regarding forward-looking statements is standard but does not overshadow the current positive metrics. Although some milestones have been delayed, the launch of OmniUltra and growth in the xPloration platform present future opportunities. Despite the lack of a market cap, these elements collectively indicate a positive sentiment, predicting a stock price increase of 2% to 8%.
OmniAb, Inc. (OABI) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary and Q&A indicate mixed sentiments. While there are positives like the xPloration program's potential and reduced expenses, the lack of clear guidance on cash runway and revenue expectations, alongside a slight increase in net loss, tempers optimism. The private placement strengthens the balance sheet, but management's evasiveness on certain details suggests uncertainty. Given these factors, the stock price reaction is likely to be neutral in the short term.
OmniAb, Inc. (OABI) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlights several positive factors: a new asset deal with significant potential milestones, a promising new program (xPloration) with growing partner interest, and a reduction in operating expenses. Despite increased net loss, the company maintains a strong cash position and has increased its royalty rate. The Q&A session confirmed positive sentiment towards the xPloration program and upcoming technology launch, though some details remain unclear. Overall, the positive elements, including strong partnership growth and strategic initiatives, suggest a likely positive stock movement.
OABI Slides
OABI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
